血清中环氧化酶-2定量测定在膀胱移行细胞癌中的临床预测价值

Clinical value of quantitative examination of cyclooxygenase-2 in serum in patients of BTCC

目的探讨血清中环氧化酶-2(COX-2)定量测定在膀胱移行细胞癌(BTCC)诊断及随访中的临床价值。方法采用酶联免疫测定(EIA)法定量测定60例BTCC患者血清中COX-2含量,同时对20例BTCC术后复查阴性患者、12例癌前病变患者、18例其他泌尿系疾病患者及25例健康对照者进行检测。结果BTCC组血清中COX-2含量显著高于其他组,COX-2含量随BTCC分期、分级增高而增加,初、复发肿瘤间COX-2含量差异无显著性。结论BTCC患者血清中COX-2水平明显升高并且同肿瘤的侵袭状态密切相关,血清中COX-2定量测定有可能成为一项有价值的用于BTCC筛查诊断和术后监测的新指标。

[Objective] To explore the clinical diagnosis and follow up value of quantitative examination of eyclooxygenase-2 （COX-2） in the serum for bladder transitional cell carcinoma （BTCC） patients for diagnosis and investigation. [Methods] Serum samples of 60 BTCC patients were examined by the quantitative Enzyme-linked immunoadsordent assay （EIA）. At the same time, 20 eases that underwent surgical procedure previously for BTCC but now free of the disease, 12 cases of pre-cancerous lesions, 18 cases of other urological diseases and 25 healthy volunteers were examined as the matched control groups. [Results] The level of COX-2 in BTCC group was significant higher than other groups and the contents of COX-2 increased with tumor grade and stage progression. There were no significant differences between the primary tumors and recurrences. [Conclusion] The contents of COX-2 in serum of BTCC patients is signifieanly higher than that in healthy individuals and other patients with urological diseases, serum COX-2 is closely related to the invasive behavior of the tumors. Serum EIA detection of COX-2 may be a new useful means for screening diagnosis and monitoring of BTCC patients.